Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» UGN-101
UGN-101
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett
Flag link:
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Upcoming events – Phase III readouts loom for Urogen and Mediwound
EP Vantage
Urogen
clinical trials
UGN-101
urothelial cancer
MediWound
NexoBrid
devices
burns
Flag link:
